

Adaptimmune Presents at ASGCT with Preclinical Proof-of-Concept Data Supporting Future Clinical Development with a Next-generation SPEAR T-cell using PRIME technology

We are pleased to inform that Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented preclinical proof-of-concept data from next-generation SPEAR T-cell (ADP-A2M4N7X19) targeting MAGE-A4 at the American Society of Gene & Cell Therapy (ASGCT) annual meeting.

Next-generation ADP-A2M4N7X19 SPEAR T-cells show potential for enhanced clinical activity with improved proliferation, survival, and infiltration of immune cells into MAGE-A4 expressing tumors in preclinical studies in vitro

- Next-generation SPEAR T-cells targeting MAGE-A4 were engineered to secrete IL-7 and CCL19 (ADP-A2M4N7X19) using “Proliferation-Inducing and Migration- Enhancing” (PRIME)¹ technology
- IL-7 stimulates T-cell proliferation and survival, and CCL19 induces infiltration of immune cells
- Naturally occurring T-cells do not express IL-7 or CCL19
- Next-generation ADP-A2M4N7X19 SPEAR T-cells were shown to produce IL-7 and CCL19 only in the presence of the MAGE-A4 cancer target
- IL-7 production by ADP-A2M4N7X19 SPEAR T-cells enhanced T-cell survival, and CCL19 production induced infiltration of immune cells
- These properties could enhance antitumor activity in the clinic
- Based on these data, the Company will initiate a Phase 1 clinical trial with ADP-A2M4N7X19 in multiple solid tumor indications

¹ PRIME technology used in collaboration with Noile-Immune Biotech